Galmed Pharmaceuticals to Present Late-Breaking Data at HEP-DART 2025 Meeting Galmed Pharmaceuticals announces a late-breaking abstract presentation at HEP-DART 2025, revealing new insights on their drug Aramchol's efficacy combined with regorafenib.

Galmed Pharmaceuticals to Present Late-Breaking Data at HEP-DART 2025 Meeting #Israel #Galmed_Pharmaceuticals #Aramchol #Regorafenib #Ramot_Gan

#REGOMUNE - a phase II #ClinicalTrial of #Regorafenib + #Avelumab in advanced 'cold' #SoftTissueSarcoma—shows that anti-angiogenic therapy modulates the #TumorMicroenvironment and boosts immune-mediated tumor destruction. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

This study evaluates the clinical efficacy of #regorafenib in combination with #avelumab in mTLS-negative #SoftTissueSarcoma patients, highlighting the potential of #antiangiogenic agents to modify the #TumorMicroEnvironment. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

#Regorafenib Induced Interstitial #Pneumonia in a Patient With Refractory Rectal Cancer
onlinelibrary.wiley.com/doi/10.1002/...

Galmed Pharmaceuticals Reports Promising Results with Aramchol and Regorafenib Combination in Cancer Studies Galmed Pharmaceuticals has announced significant findings on the effectiveness of Aramchol in boosting the effects of Bayer's Regorafenib against GI cancers, as reported by VCU's research.

Galmed Pharmaceuticals Reports Promising Results with Aramchol and Regorafenib Combination in Cancer Studies #Israel #Tel_Aviv #Galmed_Pharmaceuticals #Aramchol #Regorafenib

US Pharmacopeia News | Labmix24 Stay up-to-date on new USP product releases, training courses and other announcements.

New US Pharmacopeia reference standards and Quality Solution Sheets are available at @Labmix24. Learn more: labmix24.com/en/pharmaceu...
 #Nadolol #Paliperidone #Pantoprazole #Pemetrexed #Permethrin #Pentazocine #Pimecrolimus #Piperacillin #Propranolol #Regorafenib #Rotigotine #Sirolimus #Sorafenib

@EASLedu Prof. Galle: #lenvatinib first line, #regorafenib second line to join #sorafenib as approved #HCC systemic rx #ilc2017

#HCC Pts got 160 mg #regorafenib daily, for 3 wks on/1wk off, or placebo. No details yet but side effects as expected per press release

@EASLnews Dr. Schierwagen: #regorafenib reduces portal pressure in animal model. Unclear how high AE burden drug could be used. #ILC2016